BeiGene is entering a new phase as it continues to build its U.S. presence. The company announced that the last piece of structural steel will be laid at its Hopewell, NJ campus This new facility will provide state-of-the-art commercial-stage U.S. biologic pharmaceutical manufacturing, late-stage research and clinical development capabilities that complement the company’s existing capabilities around the world… " The new campus will have approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing space with the ability to add 600,000 more over time. First announced in 2021, BeiGene’s investment in this project is expected to total approximately $700 million. Construction is expected to be complete next year.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BGNE:
- Leap Therapeutics news ‘disappointing at first glance,’ says Piper Sandler
- Leap Therapeutics price target lowered to $2 from $3 at Mizuho
- Leap Therapeutics provides update on BeiGene option agreement for DKN-01
- Prelude Therapeutics, BeiGene enter clinical trial collaboration
- BeiGene price target raised to $262 from $213 at Cowen